Newport Beach, Calif.-based MediPines Corp. announces that the U.S. FDA has cleared its MediPines Gas Exchange Monitor, which provides clinicians with real-time pulmonary parameters and insights to support triage and treatment decisions for respiratory conditions.
Moreover, the MediPines Gas Exchange Monitor integrates a set of respiratory parameters and indices analyzed from a patient’s normal breathing samples. Such data provides clinicians with point-of-care information on pulmonary gas exchange—information, company officials say, that was previously only available through invasive methods.
Specifically, the MediPines Gas Exchange Monitor provides critical parameters including respiratory rate, oxygen saturation, pulse rate, respiratory quotient, and end-tidal carbon dioxide. The portable device also provides indices such as oxygen deficit.
Steve Lee, CEO of MediPines Corp., believes the device will strongly impact the medical equipment sector. “This is a result of years of scientific and medical research working with the world-renowned respiratory physiology team led by Dr. John B. West,” Lee adds. “This device is a significant step forward in advancing respiratory medicine, providing hospitals with vital respiratory care measurements to aid clinicians in diagnosis and treatment, immediately at the point-of-care.”